Viking Therapeutics Shares Soar 30% as Obesity Drug Trial Shows 97% Weight Loss Retention on Reduced Dosing
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Tue, 22 September 2026
What it is about
Eli LillyNovo Nordisk WegovyEli Lilly ZepboundNasdaqNovo NordiskCantor FitzgeraldTherapeutics IncSan Diego, California, United States
Who published it, and when
How it spread - 1 original report
Tue, 22 September 2026
1 report- ibtimes.com.au13:56first to report
Viking Therapeutics shares rose nearly 30% after maintenance-trial results showed patients retained most of their weight loss on less frequent dosing of experimental drug VK2735.